Product Description
ASP0113 is an investigational vaccine candidate designed to prevent CMV disease and associated complications in CMV-seropositive HCT recipients.
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intramuscular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Astellas Pharma
Company Location: NEW YORK NY 10005
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Transplantation Unspecified|Allogeneic Stem Cell Transplant
Phase 2: Other|Transplantation Unspecified|Kidney Transplant
Phase 1: Cytomegalovirus Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2013-000903-18 | P3 |
Completed |
Allogeneic Stem Cell Transplant |
2022-03-01 |
|
| 2013-000464-29 | P2 |
Completed |
Transplantation Unspecified|Kidney Transplant |
2021-12-03 |
|
| HELIOS | P3 |
Completed |
Transplantation Unspecified |
2017-09-28 |
|
| 0113-CL-2001 | P2 |
Completed |
Kidney Transplant |
2016-05-13 |